Skip to main content
PEPTARA LABS
Get Started
Peptara Labs LL-37 5mg vial
Human cathelicidin

LL-37 Peptide for Sale

Published by · Updated · How we research and check our pages

Human Antimicrobial Peptide, Studied in Labs

LL-37 peptide from Peptara Labs (peptaralabs.io) is a 5mg research vial of the human cathelicidin, the only antimicrobial peptide of its family made in the human body. A vial costs $66 USD, the LL-37 Black Friday price: 45% off the regular $120. Its batch certificate of analysis is pending, so no purity figure is claimed yet. On pre-order: Ships as soon as stock arrives. Arrival follows transit. It is sold for research use only.

$66 USDWas $120 USD

Black Friday price, 45% off, ends November 30

Flat $35 tracked shipping5mg per vial

Ships as soon as stock arrives

1vial

$66 USD

Was $120

$66.00 per vialWas $120.00Black Friday price

Add 2 more, unlock 50%

Vials of any product count together in your cart: 1 to 2 vials 45% off, 3 to 4 vials 50% off, 5 to 9 vials 55% off, 10 or more 60% off. No code is added on top.

Batch certificate pending
Ships as soon as stock arrives
Peptara Labs LL-37 5mg vial

Shipping, delivery and certificate status

Shipping
Flat $35, tracked worldwide to supported markets
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Included
Vial · Batch certificate pending · Order support on WhatsApp

Buyer facts

What comes with an LL-37 research order?

The order includes one sealed 5mg vial of lyophilized LL-37. The batch certificate is pending. The table lists the current price and shipping terms. The scientific references describe the molecule, but they do not verify the contents of this batch.

DetailPeptara Labs LL-37 (5mg)Where to check it
Vial5mg of lyophilized LL-37 powder in one sealed vialCatalog and order summary
Price$66 USD, the LL-37 Black Friday price: 45% off the regular $120The order panel above
AvailabilityPre-order. Ships as soon as stock arrives. Arrival follows transit.The order panel above
CertificateBatch certificate pending. No purity figure is claimed yet.Certificates of analysis
Delivery after dispatchShips as soon as stock arrives · After dispatch: 5 to 10 business daysOrder summary and shipping details
StatusLaboratory research onlyResearch and safety record below

Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.

Research vial
Batch certificate pending
Delivery information with your order
Order support

Share or cite this page

Add as preferred on Google

Before you buy

What should be checked before buying LL-37?

Identity and purity answer different questions. A mass test checks whether the sample matches LL-37. HPLC checks the share of the sample represented by the measured peptide. A high purity figure alone cannot establish the right sequence.

  • LL-37 has 37 amino acids and a reference molecular weight near 4,493 Da. A certificate should identify the sample and the method that measured it.
  • The salt form should be named. Acetate and trifluoroacetate labels appear in reagent catalogs, and the form affects how the mass is described.
  • Scrambled and citrullinated variants are separate laboratory materials. A certificate should name the sequence being supplied rather than use LL-37 as a loose family label.
  • The certificate should belong to the supplied batch. This page claims no purity or measured identity while the certificate remains pending.

The peptide purity guide explains supplier checks. The certificates page lists documents that have been published and marks pending records.

Sources: UniProt P49913, checked October 7, 2026; PubChem CID 16198951, checked October 7, 2026.

The short answer

What is LL-37?

LL-37 is the only human member of the cathelicidin peptide family. The CAMP gene makes its larger precursor, hCAP18. Enzymes release the 37 amino acid segment from that protein. Neutrophils, a type of white blood cell, and epithelial cells lining body surfaces make the precursor.

Its name describes its sequence: the first two amino acids are leucines, written LL, and its length is 37 amino acids. The peptide has a positive charge and can form a helix with water-facing and lipid-facing sides. Those features help explain its behavior next to cell membranes.

PropertyReference identity
ClassThe only human cathelicidin
Length37 amino acids
PrecursorhCAP18, encoded by CAMP
ChargeAbout +6 at normal body pH
StructureA helix with water-facing and lipid-facing sides
Main sourcesNeutrophils and epithelial cells
SequenceLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
FormulaC205H340N60O53
Molecular weightAbout 4,493 Da

Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Durr et al., 2006, Biochimica et Biophysica Acta (PMID 16716248); Gennaro and Zanetti, 2000, Biopolymers (PMID 10931440); UniProt P49913, checked October 7, 2026; PubChem CID 16198951, checked October 7, 2026.

The Science

How LL-37 works in research models

LL-37 has membrane activity and immune-signaling activity. Laboratory tests examined these separately, because a microbial membrane, an immune cell and a skin sample can respond differently to the same peptide. Salt and serum also change the behavior seen in simple culture tests.

How does LL-37 work?

Its positive charge draws it toward negatively charged microbial surfaces. In bacterial tests, it disrupted membranes and bound lipopolysaccharide, usually shortened to LPS. The bacterial species and the salt content of the test medium affected activity.

What does LL-37 do besides kill microbes?

Cell tests found that LL-37 drew neutrophils, monocytes and T cells toward it through FPRL1, also called FPR2. That is a movement signal for immune cells, measured in laboratory conditions.

What does vitamin D have to do with LL-37?

The CAMP gene has a vitamin D response element. The active form of vitamin D switched on this gene in cell studies. Researchers found the same gene feature in primates but not mice, which matters when comparing models.

Why context matters

Serum components can blunt LL-37 activity in laboratory tests. Reviews also record damage to host cells as concentration rises. A result from a simple test dish does not establish how the peptide behaves in people.

Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gombart et al., 2005, FASEB Journal (PMID 15985530).

Research areas

Common research areas

Antimicrobial and biofilm models

Laboratory research examines microbial growth, membrane contact and communities of microbes called biofilms. These are controlled models whose conditions affect the observations.

Immune-cell signaling

Researchers track immune-cell movement and receptor signals. These studies ask how a host-defense peptide links membrane activity to immune responses.

Skin inflammation research

Rosacea work found altered cathelicidin levels and fragments. Psoriasis research described LL-37 as a T-cell autoantigen, a molecule recognized by the immune system. These are disease associations.

Wound research

Two human trials studied an LL-37 product in venous leg ulcers. The larger trial found no significant healing difference across the whole study group. Neither trial verifies this research vial.

Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Yamasaki et al., 2007, Nature Medicine (PMID 17676051); Lande et al., 2014, Nature Communications (PMID 25470744); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253).

Comparison

How does LL-37 compare with thymosin alpha-1 and KPV?

These peptides share research topics, but they have different origins and evidence records. A name in an immune-research list does not establish that the compounds work alike.

PeptideIdentity and researchHuman evidence and status
LL-37Human cathelicidin; microbial membranes and immune-cell signalingTwo small wound trials; no medicine approval
Thymosin alpha-1A separate immune-signaling peptideIts own page sets out the clinical evidence and country-specific regulator status
KPVThe Lys-Pro-Val fragment of alpha-MSH; inflammatory signaling researchIts own page separates cell and mouse findings from the absent human record

ARA-290, an EPO-derived peptide studied in small nerve trials, is on the ARA-290 peptide page.

Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Durr et al., 2006, Biochimica et Biophysica Acta (PMID 16716248); Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026.

Evidence

What did the LL-37 studies measure?

The record includes laboratory mechanisms, skin-disease associations and two human wound trials. Keeping those study types separate makes the findings easier to read. The human trials studied their own LL-37 products, rather than Peptara Labs' pending batch.

1998: microbial membranes

Model: Bacteria in laboratory cultures.

Reported: The authors measured activity against many bacteria. Some organisms resisted LL-37 in salty media. Tests also found E. coli membrane disruption and binding to LPS, a component of bacterial surfaces.

2000: immune signaling

Model: Human neutrophils, monocytes and T cells in laboratory tests.

Reported: Immune cells moved toward LL-37 through FPRL1. The receptor is also called FPR2. This mapped a signaling action beyond direct contact with microbial membranes.

2005: the CAMP gene

Model: Gene and cell studies.

Reported: The active form of vitamin D switched on CAMP through a vitamin D response element. The same gene feature appeared in primate genomes but not mouse genomes.

2007 and 2014: skin associations

Model: Rosacea skin samples and psoriasis immune research.

Reported: The rosacea paper recorded high cathelicidin levels and different fragments. The psoriasis paper described LL-37 as a T-cell autoantigen. These papers examined disease biology.

2014: safety in a small trial

Model: 34 people with hard-to-heal venous leg ulcers, compared with placebo.

Reported: The first human trial mainly examined safety and recorded no safety concerns. Its small population limits what that observation can establish.

2021: the larger wound trial

Model: 148 people with venous leg ulcers in the HEAL LL-37 phase IIb trial.

Reported: The study found no significant healing difference versus placebo across the whole group. A finding in a subgroup with large wounds called for a new study. The developer called the studied product ropocamptide.

The whole-group result of the 2021 trial comes before its subgroup finding. A subgroup can suggest another research question, but it cannot replace the main comparison. Likewise, a small trial without recorded safety concerns cannot establish safety over longer periods.

Sources: Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gombart et al., 2005, FASEB Journal (PMID 15985530); Yamasaki et al., 2007, Nature Medicine (PMID 17676051); Lande et al., 2014, Nature Communications (PMID 25470744); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253).

What is not known

What is not known about LL-37?

The papers cited here give no validated human half-life for LL-37. Half-life means the time for its measured level to fall by half. Serum binding and other interactions also affect activity, so laboratory strength is not a substitute for a study of how it moves through the body.

The side-effect record is incomplete. Reviews report host-cell membrane damage at higher concentrations. The two wound trials were small, and their safety observations cannot settle questions about other settings or longer exposure.

The FDA states concerns about possible immune reactions, peptide impurities and how the material is characterized. It also lists nonclinical signals involving male reproduction and tumor growth in some tissues. Those concerns remain on the FDA page even though the compounding nomination was withdrawn.

Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026.

Evidence ledger

LL-37 evidence and regulator ledger

The literature and regulator checks were completed on October 7, 2026. The table puts both human trials beside the regulator record. Laboratory findings, trial observations and compounding-list status answer different questions.

RecordDesign and sizeWhat was reported
2014 wound trialPlacebo-controlled, 34 people with venous leg ulcers; mainly safetyNo safety concerns recorded in this small study
2021 HEAL LL-37Phase IIb, 148 people with venous leg ulcersNo significant healing difference versus placebo in the whole group; subgroup finding called for a new study
FDA safety-risk listCathelicidin LL-37 appears under nominated but withdrawn, rather than Category 2Immune-reaction, impurity and nonclinical safety concerns remain listed; withdrawal is not clearance
July 2026 FDA meetingSeven other substances were on the advisory meeting agendaLL-37 was not among those substances; that meeting provides no LL-37 clearance

Sources: Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026; FDA advisory meeting page, July 23 to 24, 2026.

Research timeline

How the LL-37 record was built

Research timeline

How the LL-37 record was built

1998: membrane tests

Laboratory work measured bacterial growth, membrane damage and LPS binding.

2000: immune-cell movement

Cell tests linked movement of immune cells toward LL-37 to FPRL1.

2005: vitamin D link

Gene studies found a vitamin D response element in human CAMP.

2007 and 2014: skin research

Separate papers examined cathelicidin in rosacea and LL-37 in psoriasis.

2014: first human trial

A placebo-controlled trial of 34 people with leg ulcers focused on safety.

2021: phase IIb

A trial of 148 people found no significant healing difference in the whole group.

2026: regulator ledger

The FDA listed LL-37 as nominated but withdrawn, with safety concerns still stated.

Your Kit

What's Included

LL-37 research vial

$66 USD Was $120 USD

Flat $35 tracked shipping · Ships as soon as stock arrives · Batch certificate pending · Order support on WhatsApp

Black Friday price, 45% off, ends November 30

Order LL-37

LL-37 5mg Vial

5mg per vial

Batch certificate

Batch certificate pending

Delivery

Ships as soon as stock arrives · After dispatch: 5 to 10 business days

Order support

Contact our team about your order or batch certificate.

Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.

Research vial
Batch certificate pending
Delivery information with your order
Order support

Your Research Order

LL-37 research vial, batch certificate status, delivery and order support.

Batch certificate

Batch certificate pending

Delivery

Ships as soon as stock arrives · After dispatch: 5 to 10 business days

Order support

Contact our team about your order or batch certificate.

Order LL-37

Research and citations

Peer-reviewed and regulator sources

  1. Vandamme et al., 2012, Cell Immunology (PMID 23246832). Review of LL-37 biology, host-cell toxicity and serum interactions.
  2. Durr et al., 2006, Biochimica et Biophysica Acta (PMID 16716248). LL-37, the human member of the cathelicidin family.
  3. Gennaro and Zanetti, 2000, Biopolymers (PMID 10931440). Cathelicidin structure and biological activities.
  4. UniProt P49913, checked October 7, 2026. Human CAMP precursor and LL-37 sequence.
  5. PubChem CID 16198951, checked October 7, 2026. LL-37 formula and molecular weight.
  6. Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536). LL-37 antimicrobial activity, membrane tests and LPS binding.
  7. De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447). Immune-cell movement through the FPRL1 receptor.
  8. Gombart et al., 2005, FASEB Journal (PMID 15985530). Vitamin D response element in the CAMP gene.
  9. Yamasaki et al., 2007, Nature Medicine (PMID 17676051). Cathelicidin patterns in rosacea.
  10. Lande et al., 2014, Nature Communications (PMID 25470744). LL-37 as a T-cell autoantigen in psoriasis.
  11. Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740). Placebo-controlled study of 34 people with venous leg ulcers.
  12. Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253). HEAL LL-37 phase IIb study of 148 people with venous leg ulcers.
  13. FDA safety-risk list, checked October 7, 2026. LL-37 nomination withdrawn; stated safety concerns remain listed. Page updated April 22, 2026.
  14. FDA advisory meeting page, July 23 to 24, 2026. Meeting agenda and substances reviewed; LL-37 was not among them.

FAQ

Buying LL-37: FAQ

Where can LL-37 peptide be bought?

Peptara Labs lists LL-37 as a 5mg research vial on this page. The vial is sold for laboratory research only and its batch certificate remains pending.

How much does LL-37 cost?

One 5mg research vial costs $66 USD, the LL-37 Black Friday price: 45% off the regular $120.

When does LL-37 ship?

Ships as soon as stock arrives. Delivery windows begin after dispatch: 5 to 10 business days.

Is the LL-37 batch certificate available?

The batch certificate of analysis is pending, so no purity figure is claimed yet. Published certificates and pending status are listed on the certificates page. No certificate publication date is promised for this batch.

What comes with an LL-37 order?

One sealed 5mg vial of lyophilized LL-37. Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.

LL-37 research FAQ

What is LL-37 peptide?

LL-37 is the only cathelicidin antimicrobial peptide made in the human body. It is 37 amino acids long and comes from the larger hCAP18 protein. Neutrophils and cells lining the skin, airways and gut make its precursor.

What has LL-37 been studied for?

Most of the record is laboratory research on microbes, immune-cell signaling and skin inflammation. Two human trials examined a separate LL-37 product in venous leg ulcers. The larger trial found no significant healing difference from placebo across the whole group.

What side effects have been reported for LL-37?

The small leg ulcer trials recorded no safety concerns during their study windows. Laboratory reviews report that LL-37 can damage host cells at higher concentrations. The FDA lists immune-reaction and impurity concerns, plus animal findings involving male reproduction and tumor growth. Safety over longer periods remains unknown.

Is LL-37 an approved medicine?

No. LL-37 has no medicine approval. Its FDA compounding nomination was withdrawn, which does not clear the listed safety concerns. Peptara Labs sells the vial for laboratory research only.

What does the name LL-37 mean?

LL names the two leucines at the start of its sequence. The number 37 is the number of amino acids in the peptide.

Where does LL-37 come from naturally?

The CAMP gene encodes hCAP18, a larger precursor protein. Enzymes cut LL-37 from that precursor. Neutrophils and epithelial cells make it as part of innate immune biology.

Does vitamin D affect LL-37?

In laboratory research, the active form of vitamin D switched on CAMP through a vitamin D response element in the gene. This describes a gene-level finding.

Is LL-37 the same as an antibiotic?

No. LL-37 is a host-defense peptide that acts on microbial membranes and also signals to immune cells. A standard small-molecule antibiotic is a different kind of compound.

Can LL-37 harm human cells?

Yes. Reviews report damage to host cells at higher concentrations. Laboratory context and concentration affect the findings, and the human safety record remains incomplete.

Is LL-37 linked to any skin conditions?

Research found altered cathelicidin patterns in rosacea and described LL-37 as a T-cell autoantigen in psoriasis. These are findings about disease biology, without evidence for LL-37 as a treatment.

Sources: Vandamme et al., 2012, Cell Immunology (PMID 23246832); Gennaro and Zanetti, 2000, Biopolymers (PMID 10931440); UniProt P49913, checked October 7, 2026; Turner et al., 1998, Antimicrobial Agents and Chemotherapy (PMID 9736536); De Yang et al., 2000, Journal of Experimental Medicine (PMID 11015447); Gombart et al., 2005, FASEB Journal (PMID 15985530); Yamasaki et al., 2007, Nature Medicine (PMID 17676051); Lande et al., 2014, Nature Communications (PMID 25470744); Gronberg et al., 2014, Wound Repair and Regeneration (PMID 25041740); Mahlapuu et al., 2021, Wound Repair and Regeneration (PMID 34687253); FDA safety-risk list, checked October 7, 2026.

Order LL-37, 5mg vial

Order LL-37. Ships as soon as stock arrives · After dispatch: 5 to 10 business days. Order support on WhatsApp.

Order Now

Batch certificate pending · Ships as soon as stock arrives · Order support on WhatsApp

Chat with us